New hope for pancreatitis: combination therapy with fenofibrat and acipimox convinced.
New hope for pancreatitis: combination therapy with fenofibrat and acipimox convinced.
hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is an illness that is triggered by high triglyceride values in the blood and causes inflammation of the pancreas. This form of pancreatitis is increasingly recognized and is potentially serious. People with this disease can experience severe pain in the upper abdominal area, nausea, vomiting and circulatory problems. The treatment of this disease is crucial because it can be associated with numerous health problems and even deaths.
The treatment options often include medication that reduces triglyceride levels in the blood. However, it is not yet certain which therapy is most effective. A current study has examined the effectiveness of different drugs, including atorvastatin calcium, fenofibrat and acipimox, either individually or in combination.
Analysis and possible changes in practice
The results of the examination indicate that the combination of fenofibrat and acipimox is particularly effective. Patient: Inside, which were treated with this combination, shorter hospital stays and a faster relief of the symptoms. In addition, this patient: lower peak values of certain blood values were measured on the inside, which indicate lower disease activity.
If these results are underpinned by further research, this could mean that the treatment standards change at HTG-AP. Doctors could often pass to use combination therapies to ensure faster and more effective treatment. However, additional studies are necessary to clarify the exact doses and possible side effects of this combination.
Explanation of basic terms and concepts
- hypertriglyceridemia: A condition in which the triglyceride level in the blood is increased. Triglycerides are a kind of fat that occurs in the blood and that long -term high values are potentially harmful to health.
- pancreatitis: an inflammation of the pancreas, an important organ that produces enzymes and hormones for digestion and blood sugar balance.
- atorvastatin calcium, fenofibrat, acipimox: medication that are used in the blood to reduce lipids, such as triglycerides.
- amylase: an enzyme that normally occurs in the pancreas and gets into the blood in large quantities.
- neutrophils (Neut): a kind of white blood cells that increase in infections and inflammation.
- C-reactive protein (CRP): A marker in the blood that indicates that there is inflammation in the body.
- Procalcitonin: an indicator of the blood, the increase of which can indicate an infection.
- Apache II scale: A valuation system that measures the severity of an acute illness, such as pancreatitis.
| Apache II Skala | ||||
|---|---|---|---|---|
| fenofibrat + acipimox | yes | fast | low | low |
| atorvastatin calcium | no | Slowly | medium | high |
combination of fenofibrat and acipimox significantly improves the treatment of HTG-AP
Introduction
The hypertriglyidemia-induced acute pancreatitis (HTG-AP) represents a serious clinical challenge associated with considerable morbidity and mortality. The aim of the present study was to evaluate the effectiveness of atorvastatin-calcium, fenofibrat and acipimox, each or in combination, in the treatment of HTG-AP.
method
The study was carried out with 150 HTG AP patients who were recorded in the First Hospital of Putian between June 2020 and December 2022. The patients were between 30 and 70 years old, with an average age of about 48 years. The study comprised 90 male and 60 female participants (ratio 3: 2). The patients were divided into the following six treatment groups: atorvastatin calcium, acipimox, fenofibrat, fenofibrat + atorvastatin-calcium, fenofibrat + acipimox and no medication. The therapeutic effects and clinical indicators of the groups were compared.
results
The patients in the groups with fenofibrat + acipimox and fenofibrat alone showed significantly shorter hospital stays as well as faster times until the relief of abdominal pain and gastrointestinal functional disorders compared to the other groups. In addition, the maximum values of amylase and cholesterol were lower in these groups.
Group
| Neut-increase (max. Value)
| crp (max. value)
| | ||
|---|---|---|---|---|
| fenofibrat + acipimox | 10 | 350 | 6 | 2 |
| fenofibrat | 12 | 370 | 7 | 3 |
| atorvastatin-calcium | 15 | 500 | 9 | 5 |
The increase in neutrophils (Neut) was also lower in the groups Fenofibrat + Acipimox, Atorvastatin-Calcium and Fenofibrat. In addition, the groups showed fenofibrat and acipimox significantly lower peak values of C-reactive protein (CRP). In contrast, patients in the Atorvastatin Calcium Group had higher procalcitonin values and a higher Apache-II score that evaluates the severity of acute pancreatitis.
conclusion
The results of this study emphasize the effectiveness of combination therapy with fenofibrat and acipimox in the treatment of HTG-AP, which leads to faster recovery and a significant improvement in clinical symptoms. These findings are of great importance for clinical practice, since combination therapy can be used extensively as an effective treatment strategy. The study emphasizes the important role of lipid-reducing active substances in the treatment of HTG-AP, but also indicates the need for further research in order to examine optimal doses and any side effects.